Feb 26 2026
Healthcare
Recent Research
CVS Group, H1 2026 results
Feb 26 2026
Meet your Healthcare Research team
CVS Group
H1 2026 results
CVS had a trading statement in January, which provided some of its H1 results. Organic top line growth was 2.7% despite weak consumer spending in the UK. The company expects to...
Malin Corporation
FY2025 results
Malin has announced its results for FY2025. Its latest estimate of its intrinsic equity value is €9.24/share, reflecting the value of its remaining investments and a significant cash...
Uniphar
Excellent FY2025 results drive big upgrades
Uniphar has reported adjusted EPS of 24.8c in FY2025, which is 7% above our forecast. There was strong organic gross profit growth of 8.9%, with all divisions performing well and...
hVIVO
FY2025 trading update reflects improved market backdrop
hVIVO has issued a trading statement for FY2025 reflecting revenue that is in line with our forecast and slightly better-than-expected EBITDA. The outlook is for a resumption in growth...
Uniphar
FY2025 trading statement reflects record organic growth
Uniphar has reported an extremely strong trading statement for FY2025. Organic gross profit growth of 9% is a record level and has translated into 21% EPS growth, which will drive...
CVS Group
Trading statement reflects results in line with expectations
CVS’s trading statement ahead of its AGM later today covers the four months to the end of October. Trading is as expected. The company expects to meet market forecasts for the...
CVS Group
Proposed change to listing and announcement of share buyback
CVS Group has announced that it intends to move from AIM to the main market of the London Stock Exchange. This is intended to give access to a deeper pool of capital. It has also...
CVS Group
FY2025 results
CVS’s FY2025 results reflect good revenue growth and margin expansion, especially given cost headwinds. Cash generation and proceeds from the sale of the Crematoria division have...
hVIVO
H1 2025 results
hVIVO has reported H1 results that are in line with expectations following its trading statement on July 22nd. The company has retained its guidance for FY2025. The industry has been...
Uniphar
H1 results reflect sharp acceleration in EPS growth
Uniphar grew its EPS by 21% in H1 2025. This is the company’s fastest rate of growth in several years and is driven by organic gross profit growth, accretion from its share buyback...
